Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Medtronic
Harvard Business School
Mallinckrodt
Colorcon

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Nitrendipine


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Nitrendipine?

Nitrendipine is an investigational drug.

There have been 9 clinical trials for Nitrendipine. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2014.

The most common disease conditions in clinical trials are Hypertension, Systolic Murmurs, and Renal Insufficiency, Chronic. The leading clinical trial sponsors are Katholieke Universiteit Leuven, KU Leuven, and West China Hospital.

There is one US patent protecting this investigational drug and seventeen international patents.

Recent Clinical Trials for Nitrendipine
TitleSponsorPhase
The Effect of Nitrendipine/Atenolol Combination on Blood Pressure Variability.Shanghai Jiao Tong University School of MedicinePhase 4
Coronavirus (COVID-19) ACEi/ARB InvestigationNational University of Ireland, Galway, IrelandPhase 4
Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid TumorAlphacait, LLCPhase 2

See all Nitrendipine clinical trials

Clinical Trial Summary for Nitrendipine

Top disease conditions for Nitrendipine
Top clinical trial sponsors for Nitrendipine

See all Nitrendipine clinical trials

US Patents for Nitrendipine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Nitrendipine ⤷  Try it Free Methods and compositions for treating infection UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS) ⤷  Try it Free
Nitrendipine ⤷  Try it Free Therapeutic approaches for treating Parkinson's disease Pharnext (Issy les Moulineaux, FR) ⤷  Try it Free
Nitrendipine ⤷  Try it Free Combination therapy Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) ⤷  Try it Free
Nitrendipine ⤷  Try it Free Synthetic linear apelin mimetics for the treatment of heart failure NOVARTIS AG (Basel, CH) ⤷  Try it Free
Nitrendipine ⤷  Try it Free Matrix and layer compositions for protection of bioactives Novus International, Inc. (St. Charles, MO) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Nitrendipine

Drugname Country Document Number Estimated Expiration Related US Patent
Nitrendipine World Intellectual Property Organization (WIPO) WO2014052836 2032-09-27 ⤷  Try it Free
Nitrendipine Australia AU2012222348 2031-03-01 ⤷  Try it Free
Nitrendipine Australia AU2012222351 2031-03-01 ⤷  Try it Free
Nitrendipine Australia AU2013224959 2031-03-01 ⤷  Try it Free
Nitrendipine Australia AU2013224960 2031-03-01 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Medtronic
Harvard Business School
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.